Skip to Main Content
CKG
Home
Home
Home
TKG
Author details
Breadcrumb
Author Details
Full Name
Peter S Nelson
Affiliation
Fred Hutchinson Cancer Center
ORCID
Career Start Year
1993
Papers
432
H Index
96
Expertise
CM4AI Collaborator
Trey Ideker (CM4AI)
PMID
Paper Title
Journal Title
Published Year
37850574
Characterization of HOXB13 expression patterns in localized and metastatic castration-resistant prostate cancer.
J Pathol
2024
37850574
Characterization of HOXB13 expression patterns in localized and metastatic castration-resistant prostate cancer.
J Pathol
2024
37796107
Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer.
Prostate
2024
37796107
Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer.
Prostate
2024
36821396
Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer.
JCI Insight
2023
36399432
Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes.
Cancer Discov
2023
37823778
Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers.
Cancer Res Commun
2023
37905039
ONECUT2 Activates Diverse Resistance Drivers of Androgen Receptor-Independent Heterogeneity in Prostate Cancer.
bioRxiv
2023
37725435
Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer models.
J Clin Invest
2023
37577653
Unraveling the Global Proteome and Phosphoproteome of Prostate Cancer Patient-Derived Xenografts.
bioRxiv
2023
37559436
Third generation quinoline-3-carboxamide transcriptional disrupter of HDAC4, HIF-1α, and MEF-2 signaling for metastatic castration-resistant prostate cancer.
Prostate
2023
38072760
Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.
Eur Urol Oncol
2023
38049604
Prostate lineage-specific metabolism governs luminal differentiation and response to antiandrogen treatment.
Nat Cell Biol
2023
36779357
Clinical, pathologic, and molecular features of amphicrine prostate cancer.
Prostate
2023
37343766
Artificial Intelligence-Based PTEN Loss Assessment as an Early Predictor of Prostate Cancer Metastasis After Surgery: A Multicenter Retrospective Study.
Mod Pathol
2023
36650259
The future of patient-derived xenografts in prostate cancer research.
Nat Rev Urol
2023
36710146
A Phase 1/2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients With Muscle-Invasive Bladder Cancer.
Clin Genitourin Cancer
2023
37333335
A genome-wide CRISPR screen in human prostate cancer cells reveals drivers of macrophage-mediated cell killing and positions AR as a tumor-intrinsic immunomodulator.
bioRxiv
2023
36821396
Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer.
JCI Insight
2023
36564459
Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer.
Prostate Cancer Prostatic Dis
2023
36697405
Author Correction: A framework for clinical cancer subtyping from nucleosome profiling of cell-free DNA.
Nat Commun
2023
36623239
Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer.
JCO Precis Oncol
2023
37440313
LSD1 promotes prostate cancer reprogramming by repressing TP53 signaling independently of its demethylase function.
JCI Insight
2023
36621992
Reply by Authors.
J Urol
2023
36621991
Pathological Effects of Apalutamide in Lower-risk Prostate Cancer: Results From a Phase II Clinical Trial.
J Urol
2023
36993558
Analysis of evolutionary dynamics and clonal architecture in prostate cancer.
bioRxiv
2023
37352376
Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor through cMYC Repression and Recruitment of the DREAM Complex.
Cancer Res
2023
37041154
Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy.
Nat Commun
2023
37533407
Pharmacological NF-κB inhibition decreases cisplatin chemoresistance in muscle-invasive bladder cancer and reduces cisplatin-induced toxicities.
Mol Oncol
2023
37559436
Third generation quinoline-3-carboxamide transcriptional disrupter of HDAC4, HIF-1α, and MEF-2 signaling for metastatic castration-resistant prostate cancer.
Prostate
2023
38072760
Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.
Eur Urol Oncol
2023
37905039
ONECUT2 Activates Diverse Resistance Drivers of Androgen Receptor-Independent Heterogeneity in Prostate Cancer.
bioRxiv
2023
38049604
Prostate lineage-specific metabolism governs luminal differentiation and response to antiandrogen treatment.
Nat Cell Biol
2023
37577653
Unraveling the Global Proteome and Phosphoproteome of Prostate Cancer Patient-Derived Xenografts.
bioRxiv
2023
37823778
Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers.
Cancer Res Commun
2023
37725435
Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer models.
J Clin Invest
2023
37533407
Pharmacological NF-κB inhibition decreases cisplatin chemoresistance in muscle-invasive bladder cancer and reduces cisplatin-induced toxicities.
Mol Oncol
2023
36993558
Analysis of evolutionary dynamics and clonal architecture in prostate cancer.
bioRxiv
2023
37352376
Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor through cMYC Repression and Recruitment of the DREAM Complex.
Cancer Res
2023
37343766
Artificial Intelligence-Based PTEN Loss Assessment as an Early Predictor of Prostate Cancer Metastasis After Surgery: A Multicenter Retrospective Study.
Mod Pathol
2023
37041154
Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy.
Nat Commun
2023
37440313
LSD1 promotes prostate cancer reprogramming by repressing TP53 signaling independently of its demethylase function.
JCI Insight
2023
37333335
A genome-wide CRISPR screen in human prostate cancer cells reveals drivers of macrophage-mediated cell killing and positions AR as a tumor-intrinsic immunomodulator.
bioRxiv
2023
36697405
Author Correction: A framework for clinical cancer subtyping from nucleosome profiling of cell-free DNA.
Nat Commun
2023
36623239
Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer.
JCO Precis Oncol
2023
36621992
Reply by Authors.
J Urol
2023
36621991
Pathological Effects of Apalutamide in Lower-risk Prostate Cancer: Results From a Phase II Clinical Trial.
J Urol
2023
36650259
The future of patient-derived xenografts in prostate cancer research.
Nat Rev Urol
2023
36779357
Clinical, pathologic, and molecular features of amphicrine prostate cancer.
Prostate
2023
36399432
Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes.
Cancer Discov
2023
1 - 50 of 864
Column Actions
Search
Recommended Authors
Natalie Kurganovs
Australian Prostate Cancer Research Centre Epworth
Career Start Year
2015
Number of shared co-authors
3
Richard J Rebello
University of Melbourne
Career Start Year
2015
Number of shared co-authors
10
Travis Gerke
The Prostate Cancer Clinical Trials Consortium
Career Start Year
2014
Number of shared co-authors
39
Xinpei Ci
Princess Margaret Cancer Centre, University Health Network
Career Start Year
2013
Number of shared co-authors
18
Estelle Li
University of British Columbia
Career Start Year
2012
Number of shared co-authors
20
Julie Livingstone
University of California los angeles
Career Start Year
2011
Number of shared co-authors
50
Alec Paschalis
The Institute for Cancer Research
Career Start Year
2009
Number of shared co-authors
17
Douglas W Strand
University of Texas Southwestern Medical Center
Career Start Year
2008
Number of shared co-authors
7
Alastair Davies
University of British Columbia
Career Start Year
2008
Number of shared co-authors
17
Anne Haegert
University of British Columbia
Career Start Year
2008
Number of shared co-authors
34
Dimple Chakravarty
Icahn School of Medicine at Mount Sinai
Career Start Year
2007
Number of shared co-authors
34
Svitlana Tyekucheva
Dana-Farber Cancer Institute
Career Start Year
2006
Number of shared co-authors
21
Hui Xue
Agricultural Genomics Institute at Shenzhen, Chinese Academy of Agricultural Sciences
Career Start Year
2005
Number of shared co-authors
57
Robert H Bell
University of British Columbia
Career Start Year
2004
Number of shared co-authors
29
Charlie E Massie
University of Cambridge
Career Start Year
2003
Number of shared co-authors
17
Anne Y Warren
Cambridge University Hospitals National Health Service Foundation Trust
Career Start Year
2003
Number of shared co-authors
20
Luke A Selth
Adelaide Medical School, University of Adelaide
Career Start Year
2002
Number of shared co-authors
37
Michael Fraser
Princess Margaret Cancer Centre, University Health Network
Career Start Year
2001
Number of shared co-authors
67
Mark C Markowski
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Career Start Year
2001
Number of shared co-authors
20
Sooryanarayana Varambally
University of Alabama at Birmingham, USA O'Neal Comprehensive Cancer Center
Career Start Year
2001
Number of shared co-authors
42
H??l??ne Hovington
Centre de Recherche du CHU de Quebec-Universite Laval (axe Oncologie)
Career Start Year
1999
Number of shared co-authors
15
Leena Latonen
Foundation for the Finnish Cancer Institute
Career Start Year
1999
Number of shared co-authors
5
Hayley C Whitaker
University College London
Career Start Year
1999
Number of shared co-authors
20
Robert Kim
University of California
Career Start Year
1996
Number of shared co-authors
32
Marshall Scott Lucia
University of Colorado School of Medicine
Career Start Year
1991
Number of shared co-authors
16
Guido Jenster
Erasmus University Medical Center
Career Start Year
1990
Number of shared co-authors
33
Christopher M Hovens
Royal Melbourne Hospital, The University of Melbourne
Career Start Year
1989
Number of shared co-authors
19
Adrie van Bokhoven
University of Colorado Anschutz Medical Campus
Career Start Year
1988
Number of shared co-authors
6
George Steven Bova
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Career Start Year
1982
Number of shared co-authors
39
Ralph Buttyan
University of British Columbia
Career Start Year
1976
Number of shared co-authors
24
row(s) 1 - 30 of 30
Collaborators
Ilsa Coleman
Fred Hutchinson Cancer Center
Co-authored papers
132
Lawrence D True
University of Washington School of Medicine
Co-authored papers
92
Bruce Montgomery
Fred Hutchinson Cancer Center, University of Washington
Co-authored papers
76
Colm Morrissey
Co-authored papers
70
Daniel W Lin
Co-authored papers
66
Eva Corey
University of Washington School of Medicine
Co-authored papers
65
Elahe A Mostaghel
University of Washington
Co-authored papers
61
Robert L Vessella
University of Washington
Co-authored papers
57
Colin C Pritchard
University of Washington, USA Brotman Baty Institute for Precision Medicine
Co-authored papers
45
Martin E Gleave
University of British Columbia
Co-authored papers
42
Stephen R Plymate
University of Washington
Co-authored papers
41
Ian M Thompson
CHRISTUS Santa Rosa Hospital-Medical Center
Co-authored papers
32
Heather H Cheng
Fred Hutchinson Cancer Center, University of Washington
Co-authored papers
28
Mary-Ellen Taplin
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
Co-authored papers
26
Evan Y Yu
University of Washington and Fred Hutchinson Cancer Research Center
Co-authored papers
25
Celestia S Higano
University of Washington and Fred Hutchinson Cancer Research Center
Co-authored papers
23
Leroy Hood
Center for Phenomic Health, The Buck Institute for Research on Aging
Co-authored papers
22
Steven P Balk
Beth Israel Deaconess Medical Center and Harvard Medical School
Co-authored papers
22
Michael C Haffner
Fred Hutchinson Cancer Center
Co-authored papers
21
Johann S de Bono
The Institute for Cancer Research
Co-authored papers
20
Philip W Kantoff
Memorial Sloan Kettering Cancer Center
Co-authored papers
20
Ladan Fazli
University of British Columbia
Co-authored papers
18
Eliezer M Van Allen
Dana-Farber Cancer Institute
Co-authored papers
18
Mark A Rubin
University of Bern
Co-authored papers
17
Arul M Chinnaiyan
University of Michigan Medical School.
Co-authored papers
17
Himisha Beltran
Dana-Farber Cancer Institute
Co-authored papers
16
Todd M Morgan
University of Michigan ann arbor
Co-authored papers
15
Dean A Troyer
Eastern Virginia Medical School
Co-authored papers
15
Alvin M Matsumoto
Co-authored papers
15
Camari Ferguson
Co-authored papers
14
1 - 30